News FDA sets new decision date for Ipsen’s FOP therapy US agency sets 23rd August deadline for palovarotene review as Ipsen files more clinical data.
News Ipsen adds Blueprint's FOP rare disease drug to pipeline for... Ipsen has added to its rare diseases pipeline after striking an agreement with US biotech Blueprint for a licence to develop and market a drug for the rare disease fibrodysplasia ossifican
News US measles elimination status at risk as cases soar Measles cases are roaring back in the US, with nearly 1,300 cases so far this year, 25 years after the disease was declared eliminated by the CDC.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
